Navigation Links
Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
Date:9/23/2008

FREDERICK, Md., Sept. 23 /PRNewswire/ -- Arisyn Therapeutics Inc. (Arisyn) announced today day that it has successfully acquired from UAF Technologies and Research, L.L.C. (UTR) a series of highly novel small molecule inhibitors with a well-defined preclinical efficacy spectrum against a variety of infectious organisms and cancer. Under the terms of the assignment, Arisyn will assume the intellectual property portfolio. In return, UTR will receive a cash assignment fee, cash payments on the achievement of certain defined milestones and royalties on future sales of derivative drugs.

The assets involved in the transaction include molecules originally developed by The Proctor and Gamble Company, which were donated in 2003 to UTR for research at the University of Arizona. The therapeutic agents which constitute the portfolio target the replication of the human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis C virus (HCV), influenza virus, herpes viruses, and also include broad based inhibitors of cancer. Lead compounds from the series for HIV and cancer have already been tested in Phase 1 human clinical trials, while a lead inhibitor of HCV has progressed to the submission of an IND application with the FDA. The compounds inhibit virus replication by a highly unique mechanism of action involving inhibition of viral RNA transcription and have been found to be safe in extensive toxicological evaluations.

"These novel inhibitors form the basis of a new strategy to treat infectious disease by targeting a critical viral replication pathway within the infected cell and turning off the production of progeny infectious virus. The therapeutic agents should be highly effective additions to the combination therapy regimens currently used to treat infectious disease and of immense benefit to the millions of individuals chronically infected with organisms such as HIV and HCV," noted Robert W. Buckheit, Jr., Ph.D., Director of Research and Development for Arisyn. "The compounds have proven efficacy and safety in preclinical studies and have shown significant promise to progress to Phase 1 human clinical trials for the treatment of HIV and cancer."

The continued preclinical and clinical development of the compound portfolio will be performed by ImQuest BioSciences, a Contract Research Organization located in Frederick, MD specializing in the development of drugs for the treatment of infectious disease and cancer. ImQuest will perform necessary preclinical and clinical studies and manage the evaluation of Arisyn's compounds in human clinical trials, as well as assist Arisyn with the discovery of next generation inhibitors of the novel therapeutic targets.

Bo Statham, UTR Manager, said he is very pleased that this promising technology has been assigned to Arisyn, a company that will focus exclusively on the development of these drugs.

About UTR

UTR is a limited liability company that was established to benefit the University of Arizona in the development of patents and other technology and to license or otherwise transfer such intellectual property to third parties.

About Arisyn Therapeutics Inc.

Arisyn Therapeutics Inc. is a privately held biotechnology company focused on the clinical development of small molecule therapeutics for infectious diseases and cancer. Arisyn's strategy is to develop novel inhibitors with unique mechanisms of action for chronic diseases without effective therapeutic options such as HIV, hepatitis, and cancer. Arisyn Therapeutics Inc. is based in Frederick, Maryland and is on the web at http://www.Arisyn.com.

About ImQuest BioSciences, Inc.

ImQuest BioSciences, a privately held U.S. company located in Frederick, Maryland is a leading provider of anti-infective therapeutic and microbicide development and anti-cancer services to the biotechnology and pharmaceutical industry. ImQuest has broad based capabilities to assist companies with the discovery and preclinical development of new therapeutics, vaccines and preventatives, as well as the management of IND-directed programs for the evaluation of active products in human clinical trials. ImQuest is on the web at http://www.imquest.com.

For further information regarding this press release, please contact:

Robert W. Buckheit, Jr., Ph.D.

Director of Research and Development

Arisyn Therapeutics Inc.

(301) 644-3921

rbuckheit@arisyn.com

Bo Statham

bostatham@comcast.net

(520) 519-9300


'/>"/>
SOURCE Arisyn Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Durham, NC (PRWEB) , ... June 23, 2016 , ... ... Odense University Hospital in Denmark detail how a patient who developed lymphedema after being ... (fat) tissue. The results could change the paradigm for dealing with this debilitating, frequent ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):